Trials / Terminated
TerminatedNCT01100658
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
Effects of Methylphenidate on Neuropsychological Functioning in Children With Attention Deficits Secondary to Childhood Cancer
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- University of Minnesota · Academic / Other
- Sex
- All
- Age
- 8 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention deficits in this population. Numerous studies have examined the effectiveness of methylphenidate in the treatment of children with attention deficit hyperactivity disorder (ADHD). However, the effectiveness of this medication for improving attention and behavioral functioning in children with medical illnesses or brain injury are less clear. Patients will be randomized to receive one week of Metadate CD (a controlled release form of methylphenidate, similar to Ritalin) and one week of placebo in a double-blind fashion.
Conditions
- ALL, Childhood
- Leukemia, Lymphoblastic
- Leukemia, Lymphoblastic, Acute
- Leukemia, Lymphoblastic, Acute, L1
- Leukemia, Lymphoblastic, Acute, L2
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
- Leukemia, Lymphocytic, Acute
- Leukemia, Lymphocytic, Acute, L1
- Leukemia, Lymphocytic, Acute, L2
- Lymphoblastic Leukemia
- Lymphoblastic Leukemia, Acute
- Lymphoblastic Leukemia, Acute, Childhood
- Lymphoblastic Leukemia, Acute, L1
- Lymphoblastic Leukemia, Acute, L2
- Lymphoblastic Lymphoma
- Lymphocytic Leukemia, Acute
- Lymphocytic Leukemia, L1
- Lymphocytic Leukemia, L2
- Brain Tumors
- Cancer of the Brain
- Cancer of Brain
- Malignant Primary Brain Tumors
- Brain Neoplasms, Malignant
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylphenidate | 1 capsule each day for 1 week, .3 mg/kg dose. |
| DRUG | Placebo | 1 capsule per day for 1 week. |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2010-04-09
- Last updated
- 2015-03-27
- Results posted
- 2011-11-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01100658. Inclusion in this directory is not an endorsement.